ALLO icon

Allogene Therapeutics

1.68 USD
+0.14
9.09%
At close Apr 30, 4:00 PM EDT
After hours
1.70
+0.02
1.19%
1 day
9.09%
5 days
4.35%
1 month
15.07%
3 months
-12.50%
6 months
-36.36%
Year to date
-23.64%
1 year
-39.13%
5 years
-94.19%
10 years
-93.28%
 

About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Employees: 361

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

153% more call options, than puts

Call options by funds: $446K | Put options by funds: $176K

121% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 14

48% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 42

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

11.26% more ownership

Funds ownership: 78.61% [Q3] → 89.87% (+11.26%) [Q4]

11% more funds holding

Funds holding: 155 [Q3] → 172 (+17) [Q4]

13% less capital invested

Capital invested by funds: $460M [Q3] → $401M (-$59M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
198%
upside
Avg. target
$9.25
451%
upside
High target
$14
733%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
27% 1-year accuracy
46 / 173 met price target
376%upside
$8
Buy
Maintained
19 Mar 2025
Canaccord Genuity
John Newman
30% 1-year accuracy
8 / 27 met price target
733%upside
$14
Buy
Maintained
14 Mar 2025
RBC Capital
Luca Issi
20% 1-year accuracy
11 / 54 met price target
495%upside
$10
Outperform
Reiterated
14 Mar 2025
Citizens Capital Markets
Reni Benjamin
20% 1-year accuracy
8 / 40 met price target
198%upside
$5
Market Outperform
Upgraded
14 Mar 2025

Financial journalist opinion

Based on 3 articles about ALLO published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present updated data from the completed Phase 1 TRAVERSE trial of ALLO-316 in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Illinois. The trial evaluated ALLO-316 in patients with advanced or metastatic renal cell carcinoma (RCC) who had progressed following immune checkpoint inhibitor and VEGF-targeted therapies. In addition, a trial-in-progress poster is also being presented to highlight the ongoing pivotal Phase 2 ALPHA3 trial, which is evaluating cemacabtagene ansegedleucel (cema-cel) as part of first-line (1L) treatment for patients with large B-cell lymphoma (LBCL).
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Neutral
Zacks Investment Research
3 weeks ago
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
Neutral
GlobeNewsWire
3 weeks ago
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast Track Designations (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with:
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Positive
Zacks Investment Research
1 month ago
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
Neutral
Seeking Alpha
1 month ago
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Tyler Van Buren - TD Cowen Michael Yee - Jefferies Brian Cheng - JPMorgan Sami Corwin - William Blair Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Asthika Goonewardene - Truist Matthew Biegler - Oppenheimer Shelby Tucker - RBC Capital Markets Samantha Semenkow - Citi Carolina Ibanez-Ventoso - Stifel Laura Prendergast - Raymond James Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call.
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2024.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Neutral
GlobeNewsWire
1 month ago
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Positive
Seeking Alpha
2 months ago
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading product, shows promise in first-line treatment of large B-cell malignancies, with significant revenue potential and positive clinical trial results. Allogene's financial health is stable, with a cash runway until Q1, 2026, and the company is rated a "Buy" for long-term, high-risk-tolerant investors.
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
Neutral
GlobeNewsWire
2 months ago
Allogene Therapeutics Announces Participation in March Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in March.
Allogene Therapeutics Announces Participation in March Investor Conference
Neutral
GlobeNewsWire
2 months ago
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced an expanded strategic collaboration with Foresight Diagnostics, Inc. to include the development of Foresight's minimal residual disease (MRD) assay as a companion diagnostic to identify patients with large B-cell lymphoma (LBCL) for treatment with cemacabtagene ansegedleucel (cema-cel).
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
Charts implemented using Lightweight Charts™